e-Drug3D

2020

BRINCIDOFOVIR

INN
BRINCIDOFOVIR

cas 444805-28-1

CLASS

ANTIINFECTIVES
ORTHOPOXVIRUS NUCLEOTIDE ANALOG DNA POLYMERASE INHIBITOR
TREATMENT OF HUMAN SMALLPOX DISEASE
ANTIVARIOLA
METABOLIZED BY SPHINGOMYELINASE

ROUTE (list)

ORAL

ATC code

J05AB12

PK parameters

F 16.8 PERCENT
Tmax 3 HOUR
VD 1230 LITER
Cl 44.1 LITER / HOUR
PPB 99.9 PERCENT
t1/2 19.3 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET DNA POLYMERASE

DrugCentral

Download SDF file

Phosphonic acid, P-[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, mono[3-(hexadecyloxy)propyl] ester

Formula:
C27H52N3O7P

Calculated chemical properties:

MW 560.68
NB_atoms 38
XLogP 4.62
PSA 140.767
NB_HD 3
NB_HA 10
fsp3 0.85
Lipinski(0=no;1=yes) 0

FDA
NDA 214460 (pdf not found) INN (BRINCIDOFOVIR) TEMBEXA (EMERGENT BIODEFENSE) APPROVAL= AP YEAR= 2021
NDA 214461 (pdf not found) INN (BRINCIDOFOVIR) TEMBEXA (EMERGENT BIODEFENSE) APPROVAL= AP YEAR= 2021